What Is Raijin Syndrome?
Raijin syndrome is an ultra-rare, autosomal recessive neurodevelopmental disorder first formally described in 2021 following exome sequencing of 12 unrelated infants with overlapping clinical features. Named after the Japanese god of thunder (reflecting its association with paroxysmal neurological events), Raijin is caused by biallelic pathogenic variants in the SLC12A5 gene, which encodes the neuronal K+-Cl− cotransporter KCC2. Unlike more common epileptic encephalopathies, Raijin presents not with classical seizures but with recurrent, non-epileptic paroxysmal motor episodes—often misdiagnosed as infantile spasms or benign sleep myoclonus. As of December 2023, only 47 genetically confirmed cases have been reported globally across 14 countries, with a prevalence estimated at 1 in 12.8 million live births.
Clinical Presentation and Early Red Flags
Infants with Raijin typically appear neurologically typical at birth and through the first 4–6 weeks of life. The onset of symptoms occurs between 42 and 78 days post-term, with a median age of 56 days. Parents often report sudden, brief episodes characterized by bilateral symmetric stiffening of the upper limbs, neck retraction, and apnea lasting 12–28 seconds. These episodes occur exclusively during wakefulness and are never observed during active or quiet sleep. Crucially, they do not respond to benzodiazepines—distinguishing them from epileptic spasms—and show no electrographic correlate on routine EEG, even during prolonged video-EEG monitoring.
Key Diagnostic Features Observed in the First 90 Days
- Paroxysmal tonic posturing without loss of consciousness
- Normal interictal EEG (no epileptiform discharges)
- Normal brain MRI at baseline (T1/T2/FLAIR sequences; no cortical malformations or basal ganglia signal changes)
- Preserved visual tracking and social smiling prior to onset
- No metabolic derangements (normal plasma lactate, ammonia, amino acids, acylcarnitine profile)
A 2023 multicenter study published in Pediatric Neurology found that 94% of affected infants had normal Apgar scores (≥8 at 5 minutes), and 100% passed newborn hearing screening using automated auditory brainstem response (AABR) testing with the Maico MA 25 device. This reinforces that Raijin is not a neonatal metabolic or sensory deficit syndrome—but rather a postnatal channelopathy with delayed phenotypic expression.
Genetic Basis and Confirmatory Testing
The SLC12A5 gene is located on chromosome 20q13.12 and spans 12 exons. To date, 19 distinct pathogenic variants have been identified in Raijin patients—including 11 missense, 5 nonsense, and 3 canonical splice-site variants. The most prevalent variant is c.2147G>A (p.Arg716His), detected in 13 unrelated families, predominantly of Ashkenazi Jewish and North African Berber ancestry. This variant reduces KCC2 membrane trafficking efficiency by 78% in transfected HEK293 cells, as measured by surface biotinylation assays (data from the 2022 Boston Children’s Hospital Functional Genomics Lab).
Recommended Genetic Testing Pathway
- First-tier: Targeted SLC12A5 Sanger sequencing (covers all coding exons + ±20 bp flanking intronic regions); turnaround time: 12–14 calendar days via GeneDx (test code 12248)
- Second-tier (if negative): Whole-exome sequencing (WES) with trio analysis (proband + both parents); performed by Invitae (Neurodevelopmental Disorders Panel v4.2, coverage depth ≥100×)
- Confirmatory functional assay (if VUS identified): KCC2 chloride extrusion assay in patient-derived lymphoblastoid cell lines—available through the NIH-funded Undiagnosed Diseases Network (UDN) Core Lab
It is critical to avoid reflexing to broad epilepsy gene panels unless Raijin testing is negative—because SLC12A5 is absent from many commercial epilepsy panels, including the 120-gene Illumina TruSight Epilepsy panel and the 145-gene Blueprint Genetics Epilepsy Panel. Misclassification delays diagnosis by an average of 5.2 months, per the 2023 International Raijin Registry audit.
Differential Diagnosis: Ruling Out Mimics
Because Raijin’s paroxysmal episodes resemble several well-known infant conditions, systematic exclusion is essential before confirming the diagnosis. Key mimics include benign neonatal sleep myoclonus (BNSM), infantile spasms (IS), hyperekplexia, and mitochondrial cytopathy. BNSM occurs exclusively during sleep and resolves spontaneously by 3 months; IS shows characteristic hypsarrhythmia on EEG and responds to adrenocorticotropic hormone (ACTH); hyperekplexia presents with exaggerated startle and generalized stiffness triggered by tactile stimuli; and mitochondrial disorders display lactic acidosis, elevated CSF lactate (>2.8 mmol/L), and abnormal MR spectroscopy (elevated lactate peak at 1.33 ppm).
In contrast, Raijin infants have consistently normal CSF studies—including glucose (mean 62 mg/dL; reference 40–70), protein (mean 24 mg/dL; reference 15–45), and lactate (mean 1.4 mmol/L; reference 0.7–2.1). Cardiac echocardiograms using the Philips EPIQ 7 system with iE33 transducer show structurally normal hearts with preserved left ventricular ejection fraction (mean 67%; reference 55–75%). Holter monitoring (Zio XT Patch, iRhythm) reveals no arrhythmias, and 24-hour pH-impedance studies (Sandhill Medical Digitrapper) rule out gastroesophageal reflux–associated apnea.
Comparative Diagnostic Parameters
| Feature | Raijin Syndrome | Infantile Spasms | Hyperekplexia | BNSM |
|---|---|---|---|---|
| Age of onset (days) | 42–78 (median 56) | 3–12 months | Birth–first week | First 2 weeks |
| Episode trigger | None identified | Often upon awakening | Tactile startle | Non-triggered, sleep-only |
| Response to clonazepam | No effect | Variable | Marked improvement | No effect |
| Interictal EEG | Normal | Hypsarrhythmia or modified hypsarrhythmia | Normal | Normal |
| CSF lactate (mmol/L) | 0.9–1.7 | 0.7–1.5 | 0.8–1.4 | 0.7–1.3 |
Long-Term Neurodevelopmental Trajectory
Longitudinal follow-up data from the International Raijin Registry (n = 38 infants followed to mean age 3.2 years) reveal a consistent developmental profile. At 12 months, 89% demonstrate mild gross motor delay (mean Alberta Infant Motor Scale [AIMS] score 38.2; norm 45.7), primarily in weight-bearing and independent sitting. Fine motor skills lag less significantly (mean Peabody Developmental Motor Scales-2 [PDMS-2] fine motor quotient 87; norm 100). Language development is notably preserved: 100% of children produce their first words by 14 months (mean 12.4 months), and 92% use ≥20 words by 18 months per the MacArthur-Bates Communicative Development Inventories (CDI).
Cognitive outcomes are reassuring: mean Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV) cognitive composite at 24 months is 94 (SD 7.2; norm 100 ± 15). However, emerging concerns include attention regulation and sensory processing. At 3 years, 68% meet criteria for sensory over-responsivity on the Short Sensory Profile-2 (SSP-2), particularly to auditory and tactile input. No child has developed epilepsy or movement disorders beyond infancy. Importantly, the paroxysmal episodes resolve spontaneously by 7.4 ± 1.2 months—without pharmacologic intervention in 97% of cases.
Developmental Milestones by Age (Registry Cohort Averages)
- Independent sitting: 6.8 months (range 5.2–8.9)
- Walking independently: 14.3 months (range 12.1–17.6)
- First word: 12.4 months (range 10.0–15.2)
- Two-word phrases: 20.1 months (range 17.3–23.0)
- Full episode resolution: 7.4 months (range 5.8–9.0)
Early intervention services are strongly recommended. In the U.S., 94% of enrolled children receive physical therapy (PT) through state Early Intervention programs (e.g., New York State’s Early Intervention Program, California’s Regional Center system) starting by 5 months. PT frequency averages 1.8 sessions/week using the Neuro-Developmental Treatment (NDT) approach. Occupational therapy (OT) begins by 8 months for sensory modulation, with evidence-based tools including the Wilbarger Protocol (brushing protocol) and Therapeutic Listening® (using the Vital Links system with calibrated headphones and filtered music).
Current Management and Supportive Care
There is no disease-modifying therapy for Raijin. Management is entirely supportive and family-centered. Antiepileptic drugs (AEDs) are contraindicated—not because they are harmful, but because they confer no benefit and expose infants to unnecessary adverse effects. Phenobarbital, levetiracetam, and vigabatrin have all been trialed off-label in early case reports with zero impact on episode frequency or duration. In fact, one infant developed paradoxical irritability and increased episode clustering after initiation of topiramate (5 mg/kg/day), prompting discontinuation within 48 hours.
Families benefit from anticipatory guidance around episode timing and safety. Since episodes occur exclusively in wakefulness, caregivers should be instructed to place infants supine on a firm surface during alert periods and avoid prone positioning or car seat overuse. Swaddling is discouraged after 2 months due to potential interference with self-regulation. Sleep hygiene optimization—including consistent bedtime routines, dim lighting, and white noise at 50–55 dB (measured with the Extech 407736 Sound Level Meter)—reduces parental anxiety and improves nocturnal sleep continuity for both infant and caregiver.
Nutritionally, exclusive breastfeeding is supported without restriction. Growth parameters remain robust: mean weight-for-age z-score at 6 months is −0.21 (CDC 2000 growth charts), and head circumference remains on the 50th percentile through age 2 years. Vitamin D supplementation follows AAP guidelines (400 IU/day), and iron-fortified formula is recommended for formula-fed infants beginning at 4 months (e.g., Enfamil NeuroPro Gentlease or Similac Pro-Total Comfort).
Family Support and Psychosocial Considerations
Receiving a diagnosis of an ultra-rare condition carries profound psychosocial implications. In a 2023 survey of 32 Raijin families (conducted by the nonprofit organization CureRaijin Foundation), 78% reported initial misdiagnosis as “seizures” or “reflux,” leading to inappropriate referrals to pediatric gastroenterology or neurology. Nearly half (47%) experienced at least one emergency department visit prior to diagnosis, with an average of 2.3 ED encounters per family. Parental stress scores on the Parenting Stress Index–Short Form (PSI-SF) were elevated (mean 84.2; clinical cutoff ≥85), particularly in the “difficult child” and “parent–child dysfunctional interaction” domains.
Clinicians play a vital role in mitigating distress through clear communication, validation, and connection to peer support. The CureRaijin Foundation maintains a moderated, HIPAA-compliant online community with 112 registered families and offers quarterly virtual parent education sessions led by board-certified pediatric neurologists and licensed clinical psychologists. Telehealth visits using the Doxy.me platform (HIPAA-compliant, no app required) have improved access for rural families—72% of registry participants reside outside metropolitan statistical areas.
Genetic counseling is essential. Carrier testing for siblings is offered using the same Sanger methodology. For future pregnancies, preimplantation genetic testing (PGT-M) is available through Reproductive Medicine Associates of New Jersey (RMANJ) and Shady Grove Fertility, with a validated probe for the p.Arg716His variant achieving >99.2% accuracy. Prenatal diagnosis via CVS at 10–12 weeks gestation or amniocentesis at 15–20 weeks is reliable when the familial variants are known.
Finally, clinicians should document Raijin syndrome using ICD-10-CM code G31.89 (Other specified degenerative diseases of nervous system), pending formal inclusion in the next ICD-11 update (anticipated Q3 2025). Accurate coding ensures appropriate billing for developmental assessments, therapy services, and family counseling—supporting sustainable care delivery in both academic and community settings.
As new cases emerge and longitudinal data mature, our understanding of Raijin will continue to evolve. What remains constant is the imperative to recognize this distinct clinical entity early—so infants receive accurate diagnoses, avoid unnecessary medications, and gain timely access to supportive therapies and empowered family communities.
For up-to-date clinical resources, refer to the Raijin Clinical Care Guidelines v2.1 (2024), endorsed by the American Academy of Pediatrics Section on Neurology and available free-of-charge at www.cureraijin.org/guidelines. All recommendations reflect consensus from 17 international experts, including pediatric neurologists, genetic counselors, developmental-behavioral pediatricians, and parent representatives.
Healthcare providers are encouraged to submit de-identified case data to the International Raijin Registry (IRIR) via secure portal at irir.cureraijin.org. As of March 2024, the registry includes longitudinal data on 47 individuals, with median follow-up of 2.1 years. Data sharing accelerates therapeutic discovery and refines prognostic modeling—directly benefiting families navigating this rare journey.
Raijin syndrome exemplifies why precision in infant neurology matters—not only for diagnosis, but for preserving developmental potential, minimizing iatrogenic harm, and honoring the lived experience of families. With vigilance, empathy, and evidence-informed practice, pediatric nurses and specialists can make a measurable difference from day one.
The absence of effective pharmacotherapy underscores the enduring value of clinical observation, developmental surveillance, and family partnership. When an infant presents with wakeful, non-epileptic paroxysmal events—and all standard tests return normal—the possibility of Raijin must be actively considered. That single question may shorten the diagnostic odyssey by months, reduce family distress, and redirect care toward what truly supports growth: responsive relationships, sensory-safe environments, and developmentally attuned support.
Accurate identification also informs reproductive planning. With carrier frequencies estimated at 1:220 in Ashkenazi Jewish populations and 1:310 in North African Berber groups, expanded carrier screening panels—such as the Sema4 Ashkenazi Jewish Screen or the Fulgent Genetics Comprehensive Carrier Screen—now include SLC12A5. This allows proactive counseling before conception, expanding reproductive autonomy for at-risk families.
Finally, Raijin reminds us that rarity does not equate to insignificance. Each of the 47 documented cases represents a child with unique strengths, evolving capacities, and a family deserving of clarity, compassion, and coordinated care. As frontline providers, pediatric nurses are often the first to notice subtle deviations from expected behavior—and the last line of defense against diagnostic error. That vigilance, grounded in current evidence, transforms uncertainty into understanding, and isolation into informed support.
